Shanghai, April 18, 2020 – In response to the pandemic of the corona virus (2019-nCoV) , Sundia’s Biology team has completed the development SARS-CoV-2 3CLPro screening platform to accelerate the development of anti-COVID-19 drug.

3CLPro is an enzyme necessary for the replication of new corona viruses (SARS-CoV-2) and therefore can be used as an effective inhibition target. Most of the corona virus functional proteins (non-structural proteins) are encoded by the ORF1ab gene, which is firstly translated into a multi-protein body (7096aa) and then cleaved by 3CLPro into multiple active proteins. Since 3CLPro is highly conserved among β-corona viruses, the selected 3CLPro inhibitors have broad-spectrum anti-corona virus activity. Studies have shown that the difference between SARS-CoV-2 and SARS-CoV’s 3CLPro is only 12 amino acids, and the homology is about 96%. The structure of the two is basically the same. Since SARS in 2003, there has been a large number of research bases targeting similar protease targets, and it has been well verified in the clinical fight against SARS-CoV-2.

Sundia’s Biology team offers a comprehensive range of pharmacology services including advanced ready-to-go Kinase selectivity platform, cell-based assay, radioisotope analysis and customized assay development services with experienced and extensive expertise, equipped with sophisticated equipments for HTS(high throughput screening). Our projects are implemented smoothly, which can effectively and efficiently ensure the progress as well as the quality of data. Contact us to accelerate your new drug research and development!

Since the outbreak of the SARS-CoV-2 pandemic, Sundia has actived company’s emergency response SOPs. We have set up a a response – team during Chinese New Year holiday and monitors the outbreak and government policies set against return to work after holiday, scientifically implemented the prevention, paid close attention to each employee’s health and safety, and made every effort to create a safe and maximizing social distance at workplace through flexible working time, work from home policies and video conferencing to reduce gathering in the company.  No infected  employees are found at Sundia.  In April 2020, Sundia has opened its  Taiwan R & D center  a  part of Sundia’s business continuity plan. The new R & D center will further enhance Sundia’s preclinical drug target screening and service capabilities and capacity for compound synthesis. We will, as always, provide you with high-quality non stop and efficient one-stop new drug development services.

About Sundia

As a leading, fully-integrated ‘one-stop-shop’ service provider, Sundia provides a variety of CRO services in drug discovery and development which includes Library Design, Parallel Synthesis, Custom Synthesis, Medicinal Chemistry, in vitro & in vivo Biology, DMPK, Process Development, Analytical Chemistry, Formulation Development, and Preclinical testing to meet clients’ specific project needs. Leveraging our rich project management and IND submission expertise, Sundia can efficiently integrate all the studies that are required for NMPA/FDA IND submissions and are compliant with global GMP standards.




Register Now!
Webinar: New Modality - Peptides Innovations and a Comprehensive Synthetic Peptide Drug Discovery Platform
June 19, 2024 at 10am ET / 07am PT / 04pm CET
View more
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all